Videos

Dr Obeng-Gyasi on Neighborhood Opportunity and Mortality in Breast Cancer

May 16th 2024

Samilia Obeng-Gyasi, MD, MPH, discusses a retrospective study on neighborhood opportunity and all-cause mortality in patients with breast cancer.

Dr Lim on Treatment With FOLFIRINOX vs NALIRIFOX in Metastatic Pancreatic Cancer

May 16th 2024

Kian-Huat Lim, MD, PhD, discusses factors influencing the choice between treatment with FOLFIRINOX or NALIRIFOX for metastatic pancreatic cancer.

Dr Dahiya on the FDA Approval of Liso-Cel for Relapsed/Refractory Follicular Lymphoma

May 16th 2024

Saurabh Dahiya, MD, FACP, discusses the FDA approval of lisocabtagene maraleucel for patients with relapsed/refractory follicular lymphoma.

Dr Baljevic on Advancements in the Management of Newly Diagnosed Multiple Myeloma

May 16th 2024

Muhamed Baljevic, MD, discusses key trial updates and advancements with quadruplet therapy in newly diagnosed multiple myeloma.

Dr Jagannath on the ODAC Meeting on the Safety of Cilta-Cel in R/R Multiple Myeloma

May 16th 2024

Sundar Jagannath, MBBS, discusses takeaways from the FDA’s ODAC consensus on safety considerations with cilta-cel in relapsed/refractory multiple myeloma.

Dr Gopal on a Case Study of a Patient With Bladder Cancer

May 16th 2024

Nikhil Gopal, MD, discusses details from a case discussion of a patient with bladder cancer.

Dr Kishtagari on the Impact of Momelotinib on the Management of Anemic Myelofibrosis

May 16th 2024

Ashwin Kishtagari, MD, discusses how momelotinib addresses unmet needs in the management of anemic myelofibrosis following disease progression on ruxolitinib.

Dr Ball on Data From from the IMerge Trial in Low– to Intermediate-Risk MDS

May 16th 2024

Somedeb Ball, MBBS, discusses data from the phase 3 IMerge trial of imetelstat vs placebo in low– to intermediate-risk myelodysplastic syndromes.

Dr Nye on Paradigm Shifts in the Management of HR+ Breast Cancer

May 16th 2024

Lauren E. Nye, MD, discusses how the expansion of targeted therapies in metastatic hormone receptor–positive breast cancer has shifted management approaches.

Dr Rosenberg on Efforts to Enhance Urothelial Cancer Treatment

May 15th 2024

Jonathan E. Rosenberg, MD, discusses ongoing and planned research efforts to enhance the frontline and beyond urothelial cancer treatment landscape.

Dr Lou on the Predictive and Prognostic Utility of Tumor Stroma Proportion in Ovarian Cancer

May 15th 2024

Emil Lou, MD, PhD, FACP, discusses the predictive and prognostic value of tumor stroma proportion for survival outcomes in ovarian cancer.

Dr Koff on Toxicities Associated With Pirtobrutinib in MCL

May 15th 2024

Jean L. Koff, MD, MS, discusses the toxicities associated with pirtobrutinib in the BRUIN trial for mantle cell lymphoma.

Dr Garje on Emerging Biomarkers in mCRPC

May 15th 2024

Rohan Garje, MD, discusses emerging biomarkers in metastatic castration-resistant prostate cancer and where the treatment field is headed.

Dr Tripathy on the Treatment of HER2+ Breast Cancer

May 15th 2024

Debu Tripathy, MD, discusses the current state of HER2-positive breast cancer treatment.

First-in-Human Study of BAY2927088 in Advanced HER2-Mutated NSCLC

May 15th 2024

Martin Dietrich, MD, PhD, provides an overview of the first-in-human study of BAY2927088, a novel TKI, in patients with advanced HER2-mutated non–small cell lung cancer.

Beamion LUNG-1: Zongertinib in Advanced HER2-Mutated NSCLC

May 15th 2024

The panel offers comprehensive insights on the Beamion LUNG-1 clinical trial, which is investigating zongertinib in patients with advanced HER2-mutated non–small cell lung cancer.

Dr Garmezy on Future Therapeutic Prospects for RCC

May 15th 2024

Meta: Benjamin Garmezy, MD discusses future therapeutic prospects for patients with variant renal cell carcinoma (RCC)

Progress in SCLC: From Deadly to Cure?

May 15th 2024

Millie Das, MD, of Stanford Cancer Center, discusses the progress in small cell lung cancer treatment.

Dr Townsend on Understanding Prostate Cancer and the Utility of Genomic Sequencing

May 15th 2024

Jeffrey P. Townsend, PhD, discusses advancements in the understanding of prostate cancer care through the utility of genomic sequencing.

Dr Iglesia on Unmet Needs in Second-Line Therapy Selection in HCC

May 14th 2024

Michael Iglesia, MD, PhD, discusses uncertainties surrounding the selection of second-line treatment approaches in hepatocellular carcinoma.